Exiqon Buys Oncotech for $45M To Build Dx Chops; First miRNA Test to Launch in 2008 | GenomeWeb
NEW YORK (GenomeWeb News) - Exiqon said today that it will acquire privately held cancer diagnostics maker Oncotech for around $45 million in an all-share deal.
 
Exiqon, based in Copenhagen, Denmark, said the combined company will market miRNA-based tests that will use Exiqon’s biomarker technology coupled with Oncotech’s cell-based diagnostics infrastructure.
 
Exiqon said it plans to launch the first of these tests next year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.